BLOOD PRODUCTS ADVISORY COMMITTEE
September 15, 2000
Briefing Information
Workshop Summary: Recruiting Blood Donors - Successful practices, July 6-7, 2000 - Gilliam Conley doc
"Quick Summary" of the Joint Meeting of the Transmissible Spongiform Encephalopathies Advisory Committee, Vaccines and Related Biological Products Advisory Committee, July 27, 2000 doc
III. CURRENT UTILITY OF SCREENING BLOOD DONORS FOR ANTIBODIES TO SYPHILIS
Current Utility of Screening Blood Donors for Antibodies to Syphilis, The FDA Framework, Chiang Syin, Ph.D. htm
Syphilis: Overview of Clinical Features and Recent Epidemiology in the United States
Prevalence of circulating T. pallidum DNA and RNA in PK™TP+/ FTAºABS + blood donors
Relationship of anti-HIBc and Serologic Tests for Syphilis (STS) to Blood Donor Behavioral Risk factors, AE Williams, K Watanabe, DI Ameti, S Kleinman, M P Busch, S Orton, GJ Nemo htm
CDC's plan of Syphilis transfusion studies to adress the discrepancies between their studies and those conducted by American Red Cross doc
Questions for the Committee, Martin Ruta, J.D., Ph.D.
IV. CLASSIFICATION OF HLA DEVICES
Classification of HLA Devices - contents
Classification of HLA Devices, FDA Introduction & Background, Sheryl A Kochman ppt htm
FDA's 510(k) Third-Party Review Program, Eric J. Rechen, FDA ppt htm
Disclaimer
The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
HLA-A Moving Target, Pel-Freez Clinical Systems LLC ppt htm
Classification of HLA Devices FDA Recommendations & Questions, Sheryl A Kochman ppt htm